Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 12:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 362 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Radical Prostatectomy Clear all
Recruiting Not applicable Interventional

Evaluating Safety and Efficacy of Prostate-sparing Radical Cystectomy

NCT05792722
View directory record Official record
Conditions
Bladder Cancer
Interventions
Prostate capsule-sparing radical cystectomy, Nerve sparing radical cystectomy
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Male only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 17, 2026, 12:21 PM EDT
Recruiting Phase 2 Interventional

Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery

NCT03541928
View directory record Official record
Conditions
High-risk Prostate Cancer, Prostate Cancer
Interventions
HSV-Tk, Valacyclovir, Bicalutamide, Leuprolide Acetate, Brachytherapy, External beam radiotherapy, Radical prostatectomy
Drug · Radiation · Procedure
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 17, 2026, 12:21 PM EDT
Recruiting Early Phase 1 Interventional

Impact of Intraoperative ICG on Functional Outc in RARP

NCT06446648
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
ICG
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Male only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 17, 2026, 12:21 PM EDT
Terminated Phase 2 Interventional

Efficacy and Safety Study of Cetuximab or Cetuximab Plus Docetaxel to Treat Prostate Cancer Before Prostatectomy

NCT00448097
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
cetuximab, docetaxel
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 17, 2026, 12:21 PM EDT
Recruiting Early Phase 1 Interventional

Pilot Study of (MR) Imaging With Pyruvate (13C) to Detect High Grade Prostate Cancer

NCT02526368
View directory record Official record
Conditions
Prostate Cancer, Localized Prostate Carcinoma
Interventions
Hyperpolarized 13C-Pyruvate, Hyperpolarized 13C,15N2-urea, Magnetic Resonance Spectroscopic Imaging
Drug · Procedure
Lead sponsor
Ivan de Kouchkovsky, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 17, 2026, 12:21 PM EDT
Completed Phase 2 Interventional Results available

Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer

NCT00500110
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, Imatinib Mesylate, Leuprolide, Goserelin Acetate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Oct 17, 2026, 12:21 PM EDT
Recruiting Not applicable Interventional

MRI-Based Machine Learning Approach Versus Radiologist MRI Reading for the Detection of Prostate Cancer, The PRIMER Trial

NCT07162194
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Targeted Prostate Biopsy, Prostate Imaging Reporting & Data System, Deep Learning Artificial Intelligence, Green Learning Artificial Intelligence, Radical Prostatectomy
Procedure · Diagnostic Test
Lead sponsor
University of Southern California
Other
Eligibility
20 Years and older · Male only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 17, 2026, 12:21 PM EDT
Completed Not applicable Interventional Results available

A Pilot Study to Enhance F18 FDG-PET Imaging of Prostate Cancers With the Metabolic Inhibitor Ranolazine

NCT01992016
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Bone Metastases, Soft Tissue Metastases, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
Ranolazine
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
19 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 3, 2018 · Synced Oct 17, 2026, 12:21 PM EDT
Completed Phase 2 Interventional Results available

Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer

NCT01088529
View directory record Official record
Conditions
Prostate Cancer
Interventions
Abiraterone Acetate, Prednisone, LHRHa
Drug
Lead sponsor
Cougar Biotechnology, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2014 · Synced Oct 17, 2026, 12:21 PM EDT
Active, not recruiting Phase 3 Interventional

Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer

NCT06235151
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma
Interventions
Copper Cu 64 PSMA I&T
Drug
Lead sponsor
Curium US LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
43
States / cities
Homewood, Alabama • Little Rock, Arkansas • Fullerton, California + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 17, 2026, 12:21 PM EDT
Terminated Not applicable Interventional

A Prospective Trial on Nerve Sparing Techniques Performed in Radical Prostatectomy

NCT04393831
View directory record Official record
Conditions
Prostate Cancer, Quality of Life
Interventions
Retzius sparing
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
40 Years to 80 Years · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 11, 2022 · Synced Oct 17, 2026, 12:21 PM EDT
Active, not recruiting No phase listed Observational

MRI And GPS Informing Choices for Prostate Cancer Treatment (MAGIC)

NCT05424783
View directory record Official record
Conditions
Prostate Cancer
Interventions
Genomic Prostate Score assay and Multi-parametric magnetic resonance imaging study of the prostate
Other
Lead sponsor
Northwestern University
Other
Eligibility
40 Years to 76 Years · Male only
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 17, 2026, 12:21 PM EDT
Completed Not applicable Interventional Results available

Cold Plasma for the Reduction of Lymphoceles Following PLND

NCT02658851
View directory record Official record
Conditions
Lymphoceles Following Pelvic Lymph Node Dissection
Interventions
J-Plasma
Device
Lead sponsor
Apyx Medical
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Celebration, Florida
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Oct 17, 2026, 12:21 PM EDT
Completed Phase 2 Interventional Results available

A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)

NCT03311555
View directory record Official record
Conditions
Prostate Cancer
Interventions
Apalutamide, Androgen deprivation, Salvage radiation therapy, Docetaxel
Drug · Radiation
Lead sponsor
Andrew J. Armstrong, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
Omaha, Nebraska • New York, New York • Cary, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Oct 17, 2026, 12:21 PM EDT
Completed No phase listed Observational

Quality of Life Following Radical Prostatectomy

NCT00373308
View directory record Official record
Conditions
Prostatic Neoplasms, Prostate Cancer
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Male only
Enrollment
888 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Oct 17, 2026, 12:21 PM EDT
Completed Early Phase 1 Interventional

Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer

NCT04301414
View directory record Official record
Conditions
Prostate Cancer
Interventions
BMS-986218 and Degarelix, Degarelix
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 17, 2026, 12:21 PM EDT
Completed Phase 4 Interventional Results available

A Study to Assess Efficacy and Safety With Solifenacin Succinate to Improve Urinary Continence After Robotic Assisted Radical Prostatectomy

NCT01371994
View directory record Official record
Conditions
Urinary Incontinence
Interventions
solifenacin succinate, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older · Male only
Enrollment
640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
58
States / cities
Homewood, Alabama • Anchorage, Alaska • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 17, 2026, 12:21 PM EDT
Terminated No phase listed Observational

Initiative to Minimize Disparities in Postoperative Prostate Cancer Care

NCT03755492
View directory record Official record
Conditions
Post Prostatectomy
Interventions
Absorbent pad for urinary incontinence
Other
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 17, 2026, 12:21 PM EDT
Withdrawn Not applicable Interventional

Health Interventions in Men Undergoing Radical Prostatectomy

NCT01748110
View directory record Official record
Conditions
Prostate Cancer, Erectile Dysfunction Following Radical Prostatectomy, Urinary Incontinence
Interventions
Intensive Fitness Intervention, TRIMM
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years to 65 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Oct 17, 2026, 12:21 PM EDT
Completed Phase 3 Interventional Results available

PROvenge Treatment and Early Cancer Treatment

NCT00779402
View directory record Official record
Conditions
Prostate Cancer
Interventions
Control, Sipuleucel-T
Other · Biological
Lead sponsor
Dendreon
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2015
U.S. locations
18
States / cities
Berkeley, California • Laguna Hills, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2018 · Synced Oct 17, 2026, 12:21 PM EDT
Completed Not applicable Interventional

Investigating and Characterizing the Immune Response to Prostate Cancer

NCT03331367
View directory record Official record
Conditions
Prostate Cancer
Interventions
Blood draw, Urine sample
Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Aug 7, 2020 · Synced Oct 17, 2026, 12:21 PM EDT
Terminated Phase 2 Interventional

A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer

NCT00672009
View directory record Official record
Conditions
Prostatic Diseases, Genital Neoplasms, Male, Urogenital Neoplasms, Genital Diseases, Male, Adenocarcinoma, Prostatic Neoplasms, Neoplasms, Glandular and Epithelial, Carcinoma
Interventions
Ixabepilone
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Oct 17, 2026, 12:21 PM EDT
Active, not recruiting Phase 2 Interventional

Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations

NCT05498272
View directory record Official record
Conditions
Prostate Cancer, BRCA1 Mutation, BRCA2 Mutation, Prostatic Adenocarcinoma, High-Risk Cancer
Interventions
Olaparib, LHRH agonist
Drug
Lead sponsor
Rana McKay, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
La Jolla, California • Baltimore, Maryland • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 17, 2026, 12:21 PM EDT
Active, not recruiting Phase 2 Interventional

Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer

NCT01990196
View directory record Official record
Conditions
Prostate Cancer
Interventions
degarelix, enzalutamide, trametinib, dasatinib
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Oct 17, 2026, 12:21 PM EDT